PubRank

Victor J Dzau

Author PubWeight™ 113.27‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res 2008 8.49
2 Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat Med 2003 8.46
3 Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med 2005 7.66
4 Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. FASEB J 2006 5.93
5 MicroRNA-mediated in vitro and in vivo direct reprogramming of cardiac fibroblasts to cardiomyocytes. Circ Res 2012 3.53
6 Mesenchymal stem cells overexpressing Akt dramatically repair infarcted myocardium and improve cardiac function despite infrequent cellular fusion or differentiation. Mol Ther 2006 2.85
7 Isolation and transplantation of autologous circulating endothelial cells into denuded vessels and prosthetic grafts: implications for cell-based vascular therapy. Circulation 2003 2.27
8 An initiative in mentoring to promote residents' and faculty members' careers. Acad Med 2004 1.95
9 Paracrine mechanisms of stem cell reparative and regenerative actions in the heart. J Mol Cell Cardiol 2010 1.95
10 Local renin angiotensin expression regulates human mesenchymal stem cell differentiation to adipocytes. Hypertension 2006 1.91
11 Atherosclerosis 2005: recent discoveries and novel hypotheses. Circulation 2005 1.87
12 Mesenchymal stem cells use integrin beta1 not CXC chemokine receptor 4 for myocardial migration and engraftment. Mol Biol Cell 2007 1.72
13 Gene therapy strategy for long-term myocardial protection using adeno-associated virus-mediated delivery of heme oxygenase gene. Circulation 2002 1.67
14 Genetic modification of mesenchymal stem cells overexpressing CCR1 increases cell viability, migration, engraftment, and capillary density in the injured myocardium. Circ Res 2010 1.60
15 Molecular genetics and genomics of heart failure. Nat Rev Genet 2004 1.60
16 Microarray gene expression profiles in dilated and hypertrophic cardiomyopathic end-stage heart failure. Physiol Genomics 2002 1.57
17 Cell cycle-dependent regulation of smooth muscle cell activation. Arterioscler Thromb Vasc Biol 2004 1.51
18 Exogenously administered secreted frizzled related protein 2 (Sfrp2) reduces fibrosis and improves cardiac function in a rat model of myocardial infarction. Proc Natl Acad Sci U S A 2010 1.51
19 Early beneficial effects of bone marrow-derived mesenchymal stem cells overexpressing Akt on cardiac metabolism after myocardial infarction. Stem Cells 2009 1.50
20 Essential role of ICAM-1/CD18 in mediating EPC recruitment, angiogenesis, and repair to the infarcted myocardium. Circ Res 2006 1.46
21 Cytokine-induced mobilization of circulating endothelial progenitor cells enhances repair of injured arteries. Circulation 2004 1.46
22 Enhanced inhibition of neointimal hyperplasia by genetically engineered endothelial progenitor cells. Circulation 2004 1.41
23 Global gene expression profiling of end-stage dilated cardiomyopathy using a human cardiovascular-based cDNA microarray. Am J Pathol 2002 1.38
24 Improving the health of the community: Duke's experience with community engagement. Acad Med 2008 1.38
25 Secreted frizzled related protein 2 protects cells from apoptosis by blocking the effect of canonical Wnt3a. J Mol Cell Cardiol 2008 1.35
26 Cardiac gene expression profiling provides evidence for cytokinopathy as a molecular mechanism in Chagas' disease cardiomyopathy. Am J Pathol 2005 1.32
27 Molecular and cell-based therapies for protection, rescue, and repair of ischemic myocardium: reasons for cautious optimism. Circulation 2004 1.22
28 Genetic engineering of mesenchymal stem cells and its application in human disease therapy. Hum Gene Ther 2010 1.19
29 Perspective: global medicine: opportunities and challenges for academic health science systems. Acad Med 2011 1.17
30 Heme-oxygenase-1-induced protection against hypoxia/reoxygenation is dependent on biliverdin reductase and its interaction with PI3K/Akt pathway. J Mol Cell Cardiol 2007 1.15
31 Training the next generation of physician-executives: an innovative residency pathway in management and leadership. Acad Med 2011 1.14
32 Liver X receptors alpha and beta regulate renin expression in vivo. J Clin Invest 2005 1.13
33 SFRP2 regulates cardiomyogenic differentiation by inhibiting a positive transcriptional autofeedback loop of Wnt3a. Stem Cells 2007 1.09
34 Hypoxia-regulated therapeutic gene as a preemptive treatment strategy against ischemia/reperfusion tissue injury. Proc Natl Acad Sci U S A 2004 1.09
35 Heme oxygenase-1 (HO-1) inhibits postmyocardial infarct remodeling and restores ventricular function. FASEB J 2006 1.09
36 Sex dependence and temporal dependence of the left ventricular genomic response to pressure overload. Physiol Genomics 2003 1.06
37 Nuclear receptor LXRalpha is involved in cAMP-mediated human renin gene expression. Mol Cell Endocrinol 2004 1.06
38 The angiotensin II type I receptor-associated protein, ATRAP, is a transmembrane protein and a modulator of angiotensin II signaling. Mol Biol Cell 2003 1.04
39 Construction of a zebrafish cDNA microarray: gene expression profiling of the zebrafish during development. Biochem Biophys Res Commun 2002 1.01
40 Endothelium-targeted gene and cell-based therapies for cardiovascular disease. Arterioscler Thromb Vasc Biol 2004 0.99
41 Endothelial healing in vein grafts: proliferative burst unimpaired by genetic therapy of neointimal disease. Circulation 2002 0.98
42 Physiological genomics of cardiac disease: quantitative relationships between gene expression and left ventricular hypertrophy. Physiol Genomics 2006 0.98
43 Identification of calcium-modulating cyclophilin ligand (CAML) as transducer of angiotensin II-mediated nuclear factor of activated T cells (NFAT) activation. J Biol Chem 2005 0.96
44 Preemptive heme oxygenase-1 gene delivery reveals reduced mortality and preservation of left ventricular function 1 yr after acute myocardial infarction. Am J Physiol Heart Circ Physiol 2007 0.95
45 Risk factor criteria. Circulation 2004 0.95
46 Clustering and heritability of insulin resistance in Chinese and Japanese hypertensive families: a Stanford-Asian Pacific Program in Hypertension and Insulin Resistance sibling study. Hypertens Res 2002 0.95
47 Angiotensin type 2 receptor is expressed in murine atherosclerotic lesions and modulates lesion evolution. Circulation 2005 0.94
48 Physiological genomics of human arteries: quantitative relationship between gene expression and arterial stiffness. Circulation 2003 0.94
49 Adult renal mesenchymal stem cell-like cells contribute to juxtaglomerular cell recruitment. J Am Soc Nephrol 2013 0.93
50 Transcription factor decoy. Circ Res 2002 0.92
51 Abi3bp is a multifunctional autocrine/paracrine factor that regulates mesenchymal stem cell biology. Stem Cells 2013 0.91
52 Genetic markers: progress and potential for cardiovascular disease. Circulation 2004 0.91
53 A global partnership in medical education between Duke University and the National University of Singapore. Acad Med 2008 0.91
54 Differential gene expression of blood-derived cell lines in familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 2004 0.90
55 Chronic recurrent myocardial ischemic injury is significantly attenuated by pre-emptive adeno-associated virus heme oxygenase-1 gene delivery. J Am Coll Cardiol 2006 0.90
56 Identification of a novel set of genes regulated by a unique liver X receptor-alpha -mediated transcription mechanism. J Biol Chem 2003 0.89
57 Mesenchymal stem cells differentiate into renin-producing juxtaglomerular (JG)-like cells under the control of liver X receptor-alpha. J Biol Chem 2010 0.88
58 Enhancing stem cell therapy through genetic modification. J Am Coll Cardiol 2005 0.88
59 Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction? Circulation 2004 0.88
60 C3orf58, a novel paracrine protein, stimulates cardiomyocyte cell-cycle progression through the PI3K-AKT-CDK7 pathway. Circ Res 2013 0.86
61 Elucidating the molecular mechanism of cardiac remodeling using a comparative genomic approach. Physiol Genomics 2003 0.86
62 Nasal vaccination with troponin reduces troponin specific T-cell responses and improves heart function in myocardial ischemia-reperfusion injury. Int Immunol 2009 0.86
63 Chromosomal distribution of the human cardiovascular transcriptome. Genomics 2003 0.85
64 Direct reprogramming of cardiac fibroblasts to cardiomyocytes using microRNAs. Methods Mol Biol 2014 0.84
65 Evolving revascularization approaches for myocardial ischemia. Am J Cardiol 2003 0.82
66 Gene and cell-based therapies for heart disease. FASEB J 2004 0.81
67 Molecular mechanism of juxtaglomerular cell hyperplasia: a unifying hypothesis. J Am Soc Hypertens 2010 0.81
68 Potential for germ line transmission after intramyocardial gene delivery by adeno-associated virus. Biochem Biophys Res Commun 2004 0.80
69 Fostering creativity: how the Duke Graduate Medical Education Quasi-Endowment encourages innovation in GME. Acad Med 2013 0.80
70 Genetic therapies for cardiovascular diseases. Trends Mol Med 2005 0.79
71 Bioluminescence resonance energy transfer identify scaffold protein CNK1 interactions in intact cells. FEBS Lett 2005 0.78
72 Targeted gene therapy for rat glomerulonephritis using HVJ-immunoliposomes. J Gene Med 2002 0.78
73 Physiological genomics: implications in hypertension research. Hypertension 2002 0.78
74 Separating the wheat from the chaff: focus on "in silico data filtering to identify new angiogenesis targets from a large in vitro gene profile data set". Physiol Genomics 2002 0.75
75 Angiotensin II type 1 receptor-associated protein is an endogenous inhibitor of angiotensin II type 1 receptor action in cardiac hypertrophy: role in check and balance. Hypertension 2010 0.75
76 Cardiovascular Research and the National Academy of Medicine: Advancing Progress in Science and Medicine: Part 2: What We Do. Circ Res 2017 0.75
77 Cardiovascular Research and the National Academy of Medicine: Advancing Progress in Science and Medicine: Part 1: Who We Are. Circ Res 2017 0.75
78 The future of Physiological Genomics. Physiol Genomics 2003 0.75
79 Molecular approaches for the treatment of atherosclerosis. Cardiol Clin 2002 0.75